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Abstract
Background: Deletion of the CDKN2A locus is centrally involved in the development of several malignancies. In
malignant pleural mesothelioma (MPM), it is one of the most frequently reported genomic alteration. MPM is strongly
associated with a patients’ asbestos exposure. However, the status of CDKN2A and the expression of the corresponding
protein, p16, in relation to MPM patient’s asbestos exposure is poorly known. Copy number alterations in 2p16, 9q33.1
and 19p13 have earlier been shown to accumulate in lung cancer in relation to asbestos exposure but their status in
MPM is unclear.
Methods: We studied DNA copy numbers for CDKN2A using fluorescence in situ hybridization (FISH) and p16 expression
by immunohistochemistry (IHC) in 92 MPM patients, 75 of which with known asbestos exposure status. We also studied,
in MPM, copy number alterations in 2p16, 9q33.1 and 19p13 by FISH.
Results: We were unable to detect an association between p16 expression and pulmonary asbestos fiber count in MPM
tumor cells. However, significantly more MPM patients with high pulmonary asbestos fiber count (> 1 million fibers per
gram [f/g]) had stromal p16 immunoreactivity than MPM of patients with low exposure (≤ 0.5 million f/g) (51.4% vs 16.
7%; p = 0.035, Chi-Square). We found that an abnormal copy number of CDKN2A in MPM tumor cells associated with a
high pulmonary asbestos fiber count (p = 0.044, Fisher’s Exact test, two-tailed). In contrast to our earlier findings in
asbestos associated lung cancer, DNA copy number changes in 2p16, 9q33 and 19p13 were not frequent in MPM
although single cases with variable copy numbers on those regions were seen.
Conclusions: We found two instances where the gene locus CDKN2A or its corresponding protein expression, is
associated with high asbestos exposure levels. This suggests that there may be biological differences between the
mesotheliomas with high pulmonary asbestos fiber count and those with low fiber count.
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Background
Asbestos fibers have been linked to mechanical and oxida-
tive DNA damage through production of reactive oxidant
species and fiber genotoxicity that can arise e.g. as gen-
omic alterations [1–3]. Asbestos have been shown to have
an important role in the etiology of some tumors such as
malignant mesothelioma, lung cancer and laryngeal
cancer [4, 5]. Alterations of CDKN2A locus and its corre-
sponding protein expression are involved in numerous
malignancies. In non-small cell lung cancer linked with
asbestos exposure CDKN2A has been shown to be inacti-
vated, mainly via deletions [6]. CDKN2A/ARF locus
encodes tumor suppressor genes p16INK4A and p14ARF that
interact with cyclin dependent kinase 4 (CDK4) and
MDM2 proto-oncogene, respectively, and connect two
important oncogenic pathways, RB and p53.
Malignant pleural mesothelioma (MPM) is a rare but
deadly tumor type that is strongly associated with patients’
asbestos exposure [2]. Up to 80–90% of MPM in men is
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estimated to be associated with asbestos exposure [7]. In
MPM, deletion of CDKN2A is the most frequently detected
chromosomal change and the most common cause for p16
protein inactivation (reviewed in [8]). Hypermethylation of
CDKN2A as a cause of loss of p16 expression in MPM has
been reported in a minority of cases [9, 10]. The frequency
of CDKN2A deletion in MPM have most often been shown
to range from 61 to 88% in primary tumors, few studies,
however, showing deletion only in one-fifth of cases [9, 11–
20]. The CDKN2A deletions, detected by fluorescence in
situ hybridization (FISH), have been exploited in differential
diagnosis of MPM and benign mesothelial proliferations on
effusions or biopsy material as well as in prognostication
aims [13, 16, 20–24]. Expression of p16, however, cannot
be used for these purposes [21]. Other genomic alterations
(or their protein products) common in MPM such as in
BAP1 (BRCA1 associated protein 1), MTAP (methylthioa-
denosine phosphorylase) and NF2 (neurofibromin 2) have
also been studied to find out the most valuable marker
combinations for differential diagnosis in MPM [25].
Only few studies - with a relatively limited number of
patients - have evaluated the CDKN2A/p16 status in rela-
tion to asbestos exposure [9, 11, 13, 15]. These studies
have shown either no significant association or a rather
complex picture, partially the result was dependent on
whether the exposure was assessed using occupational
history or by asbestos fiber count. In this work we studied
the relation between the patients’ pulmonary asbestos
fiber counts determined by electron microscopy and the
CDKN2A/p16 status in 92 MPM. Moreover, we report
here for the first time p16 immunoreactivity in MPM in
stromal cells and show a significant association between
p16 positive stromal staining and asbestos exposure.
In MPM, the asbestos-related genomic changes reported
mainly consist of copy number alterations such as dele-
tions in 14q11.2-q21, 6q, 17p, and 22q and DNA methyla-
tion changes [26–28]. As we have earlier shown in lung
cancer asbestos exposure-related accumulation of copy
number alterations in 2p16, 9q33.1 and 19p13 [29, 30], we
also studied the same loci in MPM. Contrary to lung can-
cer, MPM had normal mean copy number in 2p16, 9q33.1
and 19p13. Nevertheless, in these loci the individuals in
high asbestos exposure group showed wider ranges of
DNA copy number than the low exposure group.
Methods
Malignant pleural mesothelioma tissue samples
Study material consisted of 92 formalin-fixed paraffin-em-
bedded (FFPE) MPM specimens from Caucasian patients.
Demographic data of the study subjects are shown in
Table 1. Pathology samples used for tissue microarrays (for
FISH or IHC) have originally been collected in Central
Hospitals in Finland as diagnostic specimens. Autopsy
specimens for pulmonary fiber count measurements have
originally been collected for forensic purposes. Guidelines
for this sampling of autopsy specimens require that they
represent an area without tumor or fibrosis, at an inter-
mediate distance from bronchus and pleura. Before elec-
tron microscopy analysis the samples were also visually
inspected at the pathology laboratory of the Finnish Insti-
tute of Occupational Health. MPMs displayed either epithe-
lioid, sarcomatoid or biphasic histology. Diagnoses of
patients were confirmed by expert pathologists and in bor-
derline cases by consensus [31, 32].
Pulmonary asbestos fiber counts, using fiber length of >
1 μm, for 75 of the MPM patients could be analyzed using
electron microscopy with energy dispersive spectrometry
[33] (Table 1). In an international recommendation con-
cerning the attribution of asbestos-related diseases to as-
bestos exposure, a pulmonary fiber count > 1 million fibers
per gram dry weight of lung tissue (f/g) is recommended to
identify individuals with a high probability of asbestos ex-
posure at work [34]. In this article a pulmonary fiber count
> 1 million f/g is referred to as a high exposure and ≥ 5 mil-
lion f/g to as very high exposure. A pulmonary fiber count
≤0.5 million f/g is referred to as a low asbestos exposure.
To heighten the contrast between high and low exposure,
eight specimens from MPM patients having pulmonary
fiber count between 0.5 and 1 million f/g were excluded
(data not shown in Table 1).
Tissue microarrays
Tissue microarray (TMA) blocks of MPM specimens were
built using Beecher instrument. Four cores of 0.1 cm in
diameter were obtained for each case. If the original sample
available was very small, four cores of 0.06 cm in diameter
or minimum two cores of 0.1 cm in diameter were ob-
tained. TMA blocks included as methodologic quality con-
trol specimens some non-tumorous pleura/lung and seven
tumors other than malignant mesothelioma (MM) (serous
ovarian or serous peritoneal carcinoma from five females,
lung adenocarcinoma and pleomorphic liposarcoma from
two males). Twenty-six serous ovarian carcinomas in TMA
from an earlier study were used as positive p16 expression
controls [35].
Routine H&E staining of sections were studied to evalu-
ate the tumors. Because some sample cores were absent in
TMA slides, somewhat different number of tumors
produced results in FISH and IHC study, the numbers of
tumors being shown in each table.
Immunohistochemistry (IHC)
For IHC, TMA sections of 2.5 μm were treated for anti-
gen retrieval in Lab Vision™ PT-module (Thermo Fisher
Scientific Inc., Fremont, USA) using citrate buffer, pH
6.0 for 10 min (Thermo Fisher Scientific Inc.). Immuno-
staining was done in Lab Vision™ Autostainer (Thermo
Fisher Scientific Inc.) using a 1:200 dilution of mouse
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monoclonal antibody for p16 (JC8) (Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, California, USA) for 60min at RT.
For detection we used BrightVision plus Poly-HRP-Anti
Ms./Rb/Rt IgG (ImmunoLogic, Duiven, Netherlands) with
chromogen AEC (Thermo Fisher Scientific Inc.) and Mayer
haematoxylin as a background stain. Our p16 staining was
further validated by comparing it to that of an accredited
medical pathology laboratory (HUSLAB, Helsinki, Finland)
p16 staining using CINtec® p16 Histology clone E6H4™
(mtm laboratories AG, Roche Diagnostics GmbH, Mann-
heim, Germany) and DAP. These stainings were made from
whole tissue sections of three cases with distinctive staining
patterns. The positive controls of twenty-six serous ovarian
carcinomas were stained for p16 using CINtec® p16 Hist-
ology clone E6H4™. Immunostained preparations were
reviewed by HW without prior knowledge of the exposure
status using an Olympus BH2 (Olympus Europa SE & Co.
KG, Hamburg), and photographed using Leica microscope
& camera system with Leica Application Suite V4.10 [Leica
Microsystems (Switzerland) Limited]. Scoring for positivity
was as follows: 0–1%= negative, 2–10% = +, 11–50% = ++,
and 51–100% = +++. For some statistical analysis, the result
was dichotomized into negative and positive (+/++/+++)
immunoreactivity. Minimum of two TMA cores per sample
were required and the highest results among the cores were
recorded. Tumor cells and stromal cells were evaluated
separately. For sarcomatoid MM, stromal cells were not
evaluated. Serous ovarian or serous peritoneal carcinoma
from five females, lung adenocarcinoma and pleomorphic
liposarcoma from two males served as quality controls in
MPM TMAs. Twenty-six serous ovarian carcinomas in a
separate TMA served as positive control cases for p16
expression.
Fluorescence in situ hybridization (FISH)
We studied DNA copy numbers in TMAs for CDKN2A at
9p21 and centromere 9 (CEP9) simultaneously in each
cell, using a dual color probe mix of centromeric probe la-
beled with Spectrum (Sp.) Green and CDKN2A locus spe-
cific probe with Sp. Orange (Vysis Inc./ Abbott Molecular
Inc., Downers Grove, IL, USA). CDKN2A copy number
was considered as abnormal when > 20% of the cells had
lost both CDKN2A signals but showed at least one CEP9
(i.e. homozygous deletion, HD), or > 20% of the cells had
only one CDKN2A signal or at least lower signal number
than that of CEP9 (hemizygous deletion), or ≥ 50% of the
cells had one CDKN2A and one CEP9 signal (monosomy).
Locus specific DNA copy numbers in 2p16, 9q33.1
and 19p13 were studied in TMAs using bacterial artifi-
cial chromosomes (BAC) as described earlier [36]. Copy
numbers of chromosomes 2, 9, 10 and 15 centromeres
were studied using a FISHBright CEP9 probe (Qbiogene,
Illkirch, France, and Kreatech Biotechnology BV,
Amsterdam, The Netherlands), CEP2 alpha satellite
DNA probe, Sp. Green-labeled centromere 9 and centro-
mere 10 probes, and Sp. Orange-labeled centromere 15
probe (Vysis Inc./Abbott Molecular, Inc.). Hybridizations
were performed according to the manufacturers’ instruc-
tions. 2p16, 9q33.1, and 19p13 were compared with
centromere copy numbers as described earlier [29].
Centromeric probe for chromosome 19 is unavailable,
thus 19p13 signals were divided by an average of centro-
meric signals of #2, #9, #10, and #15.
FISH preparations were analysed using a Zeiss AxioIma-
ger.Z1 fluorescence microscope (Zeiss, Jena, Germany),
without prior knowledge of the exposure status or
clinico-pathological data. Efficiency of hybridization was
evaluated with lymphocytes serving as internal controls.
FISH signals were scored in 30 to 200 non-overlapping
interphase nuclei.
Statistical methods
Chi-Square test and Fisher’s Exact test were used to
test the differences between asbestos fiber exposure
Table 1 Demographic data of the study subjects in MPM microarrays
Malignant pleural mesothelioma n = 92 Quality controlsb
Asbestos fiber counta
≥ 1.0 × 106 f/g
Asbestos fiber
counta 0–0.5 × 106 f/g
Fiber count
not available
n = 53 n = 22 n = 17 n = 7
Gender, male 50 (94%) 16 (73%) 8 (47%) 2 (29%)
Age, mean ± SD, y 63.7 ± 8.7 68.1 ± 10.2 61.5 ± 8.3 56.9 ± 9.4
Pulmonary fiber counta, median (range), million f/g 8.9 (1.1–1000) 0.2 (0–0.5) NA 0.8 (0.4–16.0)c
Mesothelioma histologic type
Epithelioid 43 (81%) 11 (50%) 9 (53%) –
Biphasic 4 (8%) 6 (27%) 3 (18%) –
Sarcomatoid 6 (11%) 5 (23%) 5 (29%) –
aPulmonary asbestos fiber counts by scanning electron microscopy (SEM) or transmission electron microscopy (TEM): million fibres per gram dry lung (detection
limit ~ < 0.1 million f/g); bMethodologic quality controls had either serous ovarian carcinoma, serous ovarian or peritoneal carcinoma, adenocarcinoma of the lung
or pleomorphic liposarcoma; cFiber counts were known for three cases only, thus controls were not used in asbestos-related analysis
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groups (very high, high, low). To measure the de-
gree of agreement with CDKN2A abnormality and
p16 staining we calculated Cohen’s Kappa (κ)
Coefficient.
Results
MPM tumors from 92 patients having either low
(≤0.5 × 106 f/g), high (≥1.0 × 106 f/g), including very
high (≥ 5.0 × 106 f/g), or unknown pulmonary asbes-
tos fiber counts (unknown exposure) were studied for
p16 immunoreactivity and CDKN2A copy number.
Furthermore, DNA copy numbers were evaluated in
genomic regions 2p16, 9q33.1, and 19p13 that earlier
in lung cancer have been found with accumulating
changes that associated with asbestos exposure [29].
Some sample cores being absent in some slides,
somewhat different number of tumors produced re-
sults in FISH and IHC study. The numbers of tumors
have been shown in each table. Result for p16 was
available for 69 MPM and for both p16 and CDKN2A
copy number were available for 62 MPM. For 65
MPM, DNA copy numbers was obtained in one to
three of the 2p16, 9q33.1, and 19p13 loci, as propor-
tional to centromere.
Protein expression of p16 in MPM
Protein expression of p16 was evaluated by IHC in
tumor cells and stromal cells in TMA core prepara-
tions (Table 2). Three of the MPMs were also studied
as an entire tissue section preparation and showed
similar staining pattern as in TMA, supporting our
approach (Fig. 1). p16 staining status did not associ-
ate with gender, age, or mesothelioma histology, nei-
ther in MPM tumor nor stromal cells as shown in
Table 2. By contrast, significantly more MPM patients
with high asbestos exposure had p16 positive stromal
staining (p = 0.035, Chi-Square) than had MPM of pa-
tients with low exposure (51.4% vs 16.7%). Positivity
of p16 in stromal cells was even more predominant
among the very highly exposed when compared with
MPM with low exposure (p = 0.018, Chi-Square)
(Table 2). In MPM tumor cells, an association be-
tween p16 expression and the asbestos fiber count
was not shown.
We also studied the relation of p16 staining between
stromal and tumor cells in each individual sample
(Table 3). Fifteen (39.5%) patients with high asbestos
count had some staining in MPM stroma but not in
tumor cells whereas only one (8.3%) patient in low ex-
posure group stained this way (p = 0.048, Fisher exact
test, two-tailed) (Table 3). One of the positive controls
stained in this way.
DNA copy number of CDKN2A in relation to centromere 9
(CEP9) in MPM
Using FISH, copy numbers for CDKN2A in 9p21 and
CEP9 could be scored in 63 MPM. Homozygous dele-
tion (HD) was the most common abnormality shown in
65% of the cases. Hemizygosity or monosomy of the
chromosome 9 were both shown in 9.5% whereas 16% of
the MPM had normal copy number. Mean signal counts
of CDKN2A and CEP9 were 0.6 and 1.54 in MPM pa-
tients with high asbestos exposure whereas in low ex-
posure patients CDKN2A and CEP9 counts were 0.8 and
1.7 (Additional file 1). The proportions of copy number
statuses in relation to various clinico-pathological fea-
tures are shown in Table 2. Abnormal DNA copy num-
ber of CDKN2A in MPM tumor cells associated with
patients’ high pulmonary asbestos fiber count (p = 0.044,
Fisher’s Exact test, two-tailed) (Table 2, Fig. 2). This as-
sociation was strongest among epithelioid MPM (p =
0.014, Fisher’s Exact test, two-tailed) (Table 2). In Add-
itional files 2 and 4, examples of FISH preparations in
MPM with different amount of pulmonary asbestos fi-
bers are shown. The CDKN2A copy number did not re-
late with age of the patient or MPM histologic type. In
contrast, there was an association with gender (p =
0.025, Fisher’s Exact test, two-tailed) (Table 2) which
reflected the higher proportion of subjects with high as-
bestos exposure among males (76%) in comparison to
females (33%) (Table 1).
When the relation of CDKN2A abnormality and p16
staining status was observed in individual MPM tumors,
low exposure group tumors with abnormal CDKN2A al-
ways were negative for p16 staining and vice versa, yet
the case numbers were small (Kappa coefficient 1.000)
(Additional file 3). Other study groups did not show
similar pattern of relation between CDKN2A copy num-
ber and p16 staining. Additional file 4 (g, h, j) shows a
sarcomatoid MPM (exposure unknown) with CDKN2A
homozygosity in 74% of the tumor cells and normal
copy number of CDKN2A and CEP9 in adjacent hepatic
cells, both being negative for p16.
DNA copy numbers in 2p16, 9q33.1, 19p13, and
chromosome 2, 9, 10, and 15 centromeres
For 65 MPM, FISH result was obtained in one to three
of the 2p16, 9q33.1, and 19p13 loci, mean count of each
chromosome centromere serving as a baseline. Mean
signal counts of the loci and centromeres #2, #9, #10
and #15 suggested that copy numbers in 2p16, 9q33.1,
and 19p13 and centromeres of chromosomes 2, 9, 10,
and 15 in majority of MPM were diploid or close to dip-
loid (Additional file 1). Nevertheless, there were some
difference in ranges of the signal counts between the
high exposure and low exposure groups as well as in the
ranges of mean signal ratios (Additional file 1), the high
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exposure group having wider ranges of chromosomal
abnormality.
Discussion
Asbestos exposure causes mechanical and oxidative
DNA damage and is linked to genomic alterations [1, 2].
In mouse studies, MM formation through asbestos ex-
posure has shown a significant role of alterations in
Cdkn2a/Arf [37] and deletion of CDKN2A is the most
frequently detected chromosomal change in human
MPM [8]. Fiber-induced CDKN2A disruption has also
been observed in a study in which mesothelioma was in-
duced in mice by instillation of either asbestos fibers or
long-fiber carbon nanotube (CNTs) into the pleural cav-
ities [38].
We studied the expression of p16 encoded by
CDKN2A in MPM from 92 patients with different
asbestos-burdens. In the MPM tumor cells, we did not
detect an association between p16 expression and asbes-
tos fiber exposure as determined by asbestos fiber count.
However, significantly more MPM patients with high
pulmonary asbestos fiber count had stromal p16 immu-
noreactivity than MPM patients with low exposure. The
p16 positive stromal staining was often present concur-
rently with negative p16 staining in tumor cells. To our
knowledge earlier studies have not reported p16 immu-
noreactivity of stromal cells in MPM.
In gynecological malignancies, p16 overexpression in
tumor cells is widely used diagnostic marker because it
associates with HPV infection indicating a higher risk
for cancer. Recently, increased stromal expression of
p16, showing gradual increase with the level of malig-
nancy, has been reported in some tumors such as malig-
nant ovarian carcinoma and endometrial carcinoma [39,
40]. However, the significance of stromal p16 immunore-
activity status is not clear.
Fig. 1 p16 staining in epithelioid malignant pleural mesothelioma (MPM-E). Both the whole section (a, c, and e; using CINtec® p16 Histology
clone E6H4™ with DAP as chromogen) and tissue array (TMA) cylinder samples (b, d, and f; using mouse monoclonal antibody for p16 [JC8] with
AEC as chromogen) are shown. All microscopic illustrations have magnification × 40. Panels a) and b) show p16 staining in the case E-161 who
had pulmonary asbestos fiber count of 0.4 × 106 fibers / gram dry weight (f/g). Tumor cells showed positivity of +++ (a) to ++ (b) while
stromal cells (arrows) were negative for p16. Panels c) and d) show p16 staining in the case E-143 who had pulmonary asbestos fiber
count of 8.9 × 106 f/g. Tumor cells showed strong positivity and stromal cells had positivity of ++ (c) to + (d). Panels e) and f) show p16
staining in the case E-250 who had pulmonary asbestos fiber count of 13.0 × 106 f/g. Tumor cells were negative for p16 whereas stromal
cells showed positivity of +++ (e) to ++ (f)
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It has been shown that increased expression of p16 could
induce senescence without a senescence-associated
secretory phenotype and limit the accumulation of DNA
damage [41]. Our result of stromal p16 expression in
highly asbestos exposed patients’ MPM may mark a re-
sponse to cell activation caused by fibers but further stud-
ies are needed. Mouse studies have produced experimental
data about some molecular changes related to fiber expos-
ure as described above [37, 38] whereas in human MPM
asbestos-related changes reported are mainly copy number
alterations and DNA methylation changes [26–28]. There
are some reports suggesting that mesotheliomas associated
with asbestos exposure have a poorer prognosis than those
not associated with the exposure [42–45].
The most frequently reported chromosomal alteration
in MPM (61% ─ 88%) is deletion of material in 9p21,
i.e. primarily CDKN2A encoding tumor suppressors
p16INK4A and p14ARF [9, 11–13, 15, 16, 18–20]. Ac-
cordingly, a majority (84.1%) of our MPM cases showed
a CDKN2A copy number abnormality, either HD or
hemizygous deletion or monosomy. The LSI CDKN2A
probe we utilized covers also CDKN2B and MTAP en-
coding sequences in 9p21. In line with our result, a com-
prehensive cytogenetic study of 17 MM cell lines has
shown that the above-mentioned genes in the heart of
the region showed HD in 82–100% of the cell lines [46].
Moreover, there were numerous other genes in 9p21
showing HD or allelic loss in 12–65% of those MM cell
lines and other additional complex chromosome 9 rear-
rangements being identified by combined chromosomal
techniques [46].
In our study, asbestos exposure of the MPM patients has
been evaluated using pulmonary asbestos fiber counts
measured with electron microscopy. We showed that
abnormal copy number of CDKN2A in MPM tumor cells
associated with high pulmonary asbestos fiber count but
not with age or MPM histologic type. An earlier study of
Hirao et al. showed a somewhat complex relation between
asbestos exposure and p16 changes. In their study, p16
alterations (deletion or methylation) were more common
in cases with lower pulmonary asbestos (fiber counts by a
method different than ours) although p16 deletions were
more common in heavy exposed group. In that study, part
of asbestos exposure of the subjects had been evaluated by
medical or occupational history [15]. In other earlier stud-
ies, exposure data obtained from work history evaluation,
CDKN2A deletion and asbestos exposure did not associate
with each other [9, 11, 13].
We found here centromere 9 (CEP9) to be diploid
when using the single probe. With the dual probe mix
including probes for CEP9 and CDKN2A, somewhat
lowered mean CEP9 signals were counted. This could be
due to the different probe used in these two analysis
types and heterogeneous specimens of genetically
disturbed cancer cells with variable changes. When
establishing cut-off values for CDKN2A FISH protocol,
Chung et al. have shown a pattern of ‘one CDKN2A
signal/one CEP9 signal’ in 6–34% of nuclei in reactive
mesothelial proliferation and further in 5% of nuclei in
MPM [13]. In MM cell lines, chromosome 9 fragments
rather than whole 9 have been shown affected by HD,
chromosomal aberrations being though various and very
Table 3 MPM and controls analyzed in relation with tumor and stromal mark in p16 IHC staining
Malignant pleural mesothelioma Positive controls Quality controls
p16 staining by tumor – stroma relation High exposurea n = 47b,c Low exposured n = 17e n = 26f n = 7
Tumor neg, Stroma neg
n (%) 17 (45) 7 (59) 1 (4%) 2 (~ 33%) h
pg 0.774
Tumor pos, Stroma neg
n (%) 2 (5) 3 (25) 4 (15%) 2 (~ 33%)i
pg 0.112
Tumor neg, Stroma pos
n (%) 15 (40) 1 (8) 1 (4%) 0 (0%)
pg 0.048*
Tumor pos, Stroma pos
n (%) 4 (10) 1 (8) 20 (77%) 2 (~ 33%)j
pg 1.000
Epithelioid and biphasic malignant pleural mesothelioma and controls analyzed in relation with tumor and stromal mark in p16 immunohistochemical (IHC)
staining. aPulmonary asbestos fiber count ≥1.0 × 106 fibres per gram dry lung (f/g); bFor two cases, tumor stained positive but stroma could not be analyzed; cFor
eight cases IHC staining was not available; dPulmonary asbestos fiber count 0–0.5 × 106 f/g; eFor five cases IHC staining was not available; fPositive controls were
serous ovarian carcinomas; gFisher’s Exact Test, two-tailed; hAdenocarcinoma of the lung and pleomorphic liposarcoma; iSerous ovarian carcinoma and serous
ovarian or peritoneal carcinoma, jSerous ovarian carcinoma and serous peritoneal carcinoma; for one serous ovarian or peritoneal carcinoma IHC staining was
not available.
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complex in MM [46]. Our CEP9 results are in line with
those reports.
This is the first report indicating a correlation between
the CDKN2A deletion status and the p16 protein levels
in MPM patients having low asbestos exposure. Earlier,
somewhat discrepant results about the relationship and
correlation of the CDKN2A deletion status and the p16
levels in MPM has been reported [9, 14, 20, 21]. Immu-
noreactivity for the proteins p14, p15, p16 and MTAP,
all encoded from DNA in 9p21, has been studied and
compared with FISH result of 9p21. MTAP protein
expression has been reported to correlate best with HD
of CDKN2A [47]. There are also other mechanisms such
as DNA methylation that can influence protein expres-
sion [10]. In our study, the CDKN2A probe in 9p21 we
used covers also MTAP and CDKN2B whereas the anti-
body in immunohistochemistry recognized specifically
CDKN2A/p16. This could cause some lack of correlation
in the high exposure MPM and controls. Moreover,
CDKN2A copy number in majority of MPM is abnormal
and thus there are relatively small numbers of cases with
normal CDKN2A copy number available for a statistical
comparison. Nevertheless, the correlation between the
CDKN2A deletion status and p16 protein levels was
shown here for the first time, interestingly only in the
low exposure group MPM. The significance of this find-
ing is unclear, but it is in line with the other findings in
this paper that suggest differences in various aspects of
CDKN2A/p16 depending on the level of asbestos
exposure.
Our studies here on locus specific DNA copy numbers
and on the centromeres of chromosomes 2, 9, 10 and 15
suggested that asbestos exposure related accumulation
of alterations in 2p16, 9q33 and 19p13 that we earlier
have showed in lung cancer [29, 30] was not comparable
in MPM. Yet we found out that the ranges of signal
count in 19p13 and 9q33 in MPM were wider with high
exposure group than with low exposure group despite
the normal mean signal count. Abnormal signals, even if
being infrequent may suggest that in asbestos-exposed
Fig. 2 Scatter plots showing the relation of the pulmonary asbestos fiber count in each individual suffering from malignant pleural mesothelioma
and a) the mean DNA copy numbers of CDKN2A at 9p21 and the centromeric locus of chromosome 9 (CEN9) or b) the ratio of the mean DNA
copy numbers of CDKN2A and CEN9 in the tumors of the patients. The x-axis scale is discontinuous to provide dynamic range from the low
(≤0.5 × 106 f/g) to high (≥1.0 × 106 f/g) and to very high fiber counts (≥5.0 × 106 f/g)
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patients these genomic regions gained disintegration due
to exposure-induced DNA damage, reflected as increased
locus copy number variation in single MPM individuals.
Interestingly, loss in 19p13.2 coinciding with the se-
quence that is recognized by our 19p13 probe has earlier
been reported in 55% of MPM but without an associ-
ation to asbestos exposure probably due to the small
number of non-exposed patients in that study [48]. Al-
though 2p changes were not reported using comparative
genomic hybridization in primary MPM tumors [49],
another study on MPM cell lines have shown gains in
2p16.2-p12, 2p11.2-q11.2, and 19p13.13, depending on
the cell passage [50].
Conclusions
In conclusion, we report here for the first time that p16
immunoreactivity in stromal cells of MPM had signifi-
cant relation with the patients’ high asbestos exposure,
suggesting that the biology of MPM in highly exposed
individuals differed from that of mesotheliomas in sub-
jects with low exposure. Additionally, abnormal copy
number of CDKN2A in MPM tumor cells associated
with high pulmonary asbestos fiber count, again suggest-
ing a biological difference between mesotheliomas de-
pending on the degree of asbestos exposure. In contrast
to the situation in lung cancer, asbestos exposure associ-
ated molecular changes in 2p16, 9q33 and 19p13 were
not frequent in MPM though single cases with variable
DNA copy numbers on those regions were seen.
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